View Printer-Friendly PDF

A Drug Development & Outsourcing Profile

Arbutus Biopharma Corporation

100-8900 Glenlyon Parkway
Burnaby BC  V5J 5J8
Canada

  • Tel: 604-419-3200
  • Fax: 604-419-3201
  • CEO: William Collier
  • Mktg:
  • R&D:
  • Licng:
  • Est:
  • Rev: $ M
  • Staff:
  • Lipids
  • Internal Medicine

Arbutus Biopharma Corporation is a publicly-traded (NASDAQ: ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We believe that Arbutus' comprehensive HBV pipeline of drugs and drug candidates optimally positions us to transform the HBV treatment landscape and to capitalize on the HBV global market opportunity.

Mfg:    Labs:

NASDAQ: ABUS

0.0042